Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 407 results
Filters: Keyword is Male  [Clear All Filters]
Found 407 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

B

Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. "Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution." AIDS Care. 2006;18(7):663-73.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. "Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants." AIDS Patient Care STDS. 2015;29(3):111-6.
Hoffman RM, Jamieson BD, Bosch RJ, et al. "Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals." J. Clin. Immunol.. 2011;31(5):873-81.
Anthony DD, Conry SJ, Medvik K, et al. "Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection." J. Infect. Dis.. 2012;206(6):969-73.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Sax PE, Komarow L, Finkelman MA, et al. "Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia." Clin. Infect. Dis.. 2011;53(2):197-202.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
Macatangay BJ, Yang M, Sun X, et al. "Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217." J. Acquir. Immune Defic. Syndr.. 2017;75(1):137-141.
Dumond JB, Rigdon J, Mollan K, et al. "Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results." J. Acquir. Immune Defic. Syndr.. 2015;70(5):510-4.

C

Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
Judge CJ, Kostadinova L, Sherman KE, et al. "CD56NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections." J. Leukoc. Biol.. 2017;102(1):171-184.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Havers FP, Detrick B, Cardoso SW, et al. "Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS ONE. 2014;9(4):e95164.
Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Krishnan S, Schouten JT, Atkinson B, et al. "Changes in metabolic syndrome status after initiation of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2015;68(1):73-80.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. "Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment." J. Acquir. Immune Defic. Syndr.. 2006;43(4):433-5.
Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Smith DM, Drumright LN, Frost SDW, et al. "Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners." J. Acquir. Immune Defic. Syndr.. 2006;43(5):582-7.
Thio CL, Smeaton L, Saulynas M, et al. "Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort." AIDS. 2013;27(2):191-201.
Mugavero MJ, Pence BW, Whetten K, et al. "Childhood abuse and initial presentation for HIV care: an opportunity for early intervention." AIDS Care. 2007;19(9):1083-7.

Pages